GB8817743D0
(en)
|
1988-07-26 |
1988-09-01 |
Fujisawa Pharmaceutical Co |
Fr901228 substance & preparation thereof
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5545522A
(en)
|
1989-09-22 |
1996-08-13 |
Van Gelder; Russell N. |
Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
|
JPH0764872A
(en)
|
1993-08-26 |
1995-03-10 |
Fujitsu Ten Ltd |
Data storage controller
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US6117679A
(en)
|
1994-02-17 |
2000-09-12 |
Maxygen, Inc. |
Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US5776905A
(en)
|
1996-08-08 |
1998-07-07 |
The Board Of Trustees Of The Leland Stamford Junior University |
Apoptotic regression of intimal vascular lesions
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
WO1999011659A1
(en)
|
1997-09-02 |
1999-03-11 |
Japan Energy Corporation |
Novel cyclic tetrapeptide derivatives and medicinal use thereof
|
JPH11335375A
(en)
|
1998-05-20 |
1999-12-07 |
Mitsui Chem Inc |
Benzamide derivative having histone deacetylase inhibiting action
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
US20070148228A1
(en)
|
1999-02-22 |
2007-06-28 |
Merrion Research I Limited |
Solid oral dosage form containing an enhancer
|
US6723338B1
(en)
|
1999-04-01 |
2004-04-20 |
Inex Pharmaceuticals Corporation |
Compositions and methods for treating lymphoma
|
EP1231919B1
(en)
|
1999-09-08 |
2015-09-30 |
Sloan-Kettering Institute For Cancer Research |
Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors
|
EP1438966B1
(en)
|
1999-12-08 |
2007-02-14 |
Cyclacel Pharmaceuticals, Inc. |
Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
CA2317003A1
(en)
|
2000-02-28 |
2001-08-28 |
Hidenori Nakajima |
Gene expression potentiator
|
JP2001348340A
(en)
|
2000-06-07 |
2001-12-18 |
Yamanouchi Pharmaceut Co Ltd |
Histone deacetylase inhibitor
|
ES2321584T3
(en)
|
2000-07-17 |
2009-06-09 |
Astellas Pharma Inc. |
FK228 REDUCED AND ITS USE.
|
AU2001285042A1
(en)
*
|
2000-08-18 |
2002-03-04 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
US7396665B2
(en)
*
|
2000-09-01 |
2008-07-08 |
Astellas Pharma, Inc. |
Method of producing FR901228
|
WO2002055017A2
(en)
|
2000-11-21 |
2002-07-18 |
Wake Forest University |
Method of treating autoimmune diseases
|
JP2005507231A
(en)
|
2001-01-10 |
2005-03-17 |
アメリカ合衆国 |
Histone deacetylase inhibitors in the diagnosis and treatment of thyroid neoplasms
|
EP1353693B1
(en)
*
|
2001-01-16 |
2005-03-16 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
|
US7219016B2
(en)
|
2001-04-20 |
2007-05-15 |
Yale University |
Systems and methods for automated analysis of cells and tissues
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
ES2310213T3
(en)
|
2001-05-02 |
2009-01-01 |
The Regents Of The University Of California |
PROCEDURE TO TREAT NEURODEGENERATIVE, PSYCHIATRIC DISORDERS AND OTHER DISORDERS WITH DEACETILASE INHIBITORS.
|
AU2002305769B2
(en)
|
2001-05-30 |
2007-07-19 |
Georgetown University |
Small molecule antagonists of Bcl2 family proteins
|
US7171311B2
(en)
|
2001-06-18 |
2007-01-30 |
Rosetta Inpharmatics Llc |
Methods of assigning treatment to breast cancer patients
|
MXPA04001612A
(en)
|
2001-08-21 |
2004-07-08 |
Fujisawa Pharmaceutical Co |
Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof.
|
US20040259772A1
(en)
|
2001-08-24 |
2004-12-23 |
Antonio Fojo |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
US20050123896A1
(en)
|
2001-10-25 |
2005-06-09 |
Benz Christopher C. |
Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
|
US7354928B2
(en)
|
2001-11-01 |
2008-04-08 |
The Regents Of The University Of Michigan |
Small molecule inhibitors targeted at Bcl-2
|
WO2003053468A1
(en)
|
2001-12-21 |
2003-07-03 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
US20030134423A1
(en)
|
2002-01-04 |
2003-07-17 |
Chu Yong Liang |
Compounds for delivering substances into cells
|
EP1482962A4
(en)
|
2002-02-15 |
2009-12-23 |
Sloan Kettering Inst Cancer |
Method of treating trx mediated diseases
|
WO2003070754A1
(en)
|
2002-02-20 |
2003-08-28 |
Minoru Yoshida |
Histone deacetylase inhibitors and process for producing the same
|
EP2266552A3
(en)
|
2002-03-04 |
2011-03-02 |
Merck HDAC Research, LLC |
Methods of inducing terminal differentiation
|
WO2003083067A2
(en)
|
2002-03-28 |
2003-10-09 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
EP1492596A1
(en)
|
2002-04-05 |
2005-01-05 |
Fujisawa Pharmaceutical Co., Ltd. |
Depsipeptide for therapy of kidney cancer
|
AU2003226408B2
(en)
|
2002-04-15 |
2007-06-14 |
Sloan-Kettering Institute For Cancer Research |
Combination therapy for the treatment of cancer
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
ATE465757T1
(en)
|
2002-08-20 |
2010-05-15 |
Astellas Pharma Inc |
INHIBITOR OF THE DEGRADATION OF THE EXTRACELLULAR MATRIX OF ARTHRODIA CARTILAGE
|
BR0314112A
(en)
|
2002-09-13 |
2005-07-12 |
Univ Virginia Commonwealth |
Combination of a) n- {5- [4- (4-methyl-piperazine-methyl) -benzoylamido] -2-methyl-phenyl} -4- (3-pyridyl) -2-pyrimidine-amine and b) a deacetylase inhibitor of histone for the treatment of leukemia
|
SE0300098D0
(en)
|
2003-01-15 |
2003-01-15 |
Forskarpatent I Syd Ab |
Use of cyclin D1 inhibitors
|
US20050222013A1
(en)
|
2003-01-16 |
2005-10-06 |
Georgetown University |
Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
|
WO2004074478A1
(en)
|
2003-02-19 |
2004-09-02 |
Astellas Pharma Inc. |
Method of estimating antitumor effect of histone deacetylase inhibitor
|
WO2004096289A1
(en)
|
2003-04-25 |
2004-11-11 |
Fujisawa Pharmaceutical Co |
Gene introduction efficiency enhancer
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
PT2238982E
(en)
|
2003-06-27 |
2013-01-22 |
Astellas Pharma Inc |
Therapeutic agent for soft tissue sarcoma
|
JP4777887B2
(en)
|
2003-07-23 |
2011-09-21 |
バイエル、ファーマシューテイカルズ、コーポレイション |
Fluoro-substituted omegacarboxyaryl diphenylureas for the treatment and prevention of diseases and conditions
|
DK1663194T3
(en)
|
2003-08-26 |
2010-07-19 |
Merck Hdac Res Llc |
Use of SAHA to treat mesothelioma
|
CN101856348A
(en)
|
2003-08-29 |
2010-10-13 |
斯隆-凯特林癌症研究所 |
The therapeutic alliance method for cancer
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
JP2007505914A
(en)
|
2003-09-18 |
2007-03-15 |
コンビナトアールエックス インコーポレーティッド |
Drug combination methods for the treatment of neoplasms
|
DK2263694T3
(en)
*
|
2003-09-25 |
2013-08-26 |
Astellas Pharma Inc |
Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
US20070110719A1
(en)
|
2003-11-14 |
2007-05-17 |
Holm Per S |
Novel use of adenoviruses and nucleic acids that code for said viruses
|
EP1689446B1
(en)
|
2003-11-14 |
2015-01-07 |
Per Sonne Holm |
Novel adenoviruses, nucleic acids that code for the same and the use of said viruses
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
EP1713460A2
(en)
|
2003-12-10 |
2006-10-25 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
US20050187148A1
(en)
|
2004-02-25 |
2005-08-25 |
Yoshinori Naoe |
Antitumor agent
|
US7951780B2
(en)
|
2004-02-25 |
2011-05-31 |
Astellas Pharma Inc. |
Antitumor agent
|
ATE437370T1
(en)
|
2004-02-27 |
2009-08-15 |
Us Gov Health & Human Serv |
PHARMACODYNAMIC TESTS USING FLOW CYTOMETRY
|
GB0405349D0
(en)
|
2004-03-10 |
2004-04-21 |
Univ Birmingham |
Cancer therapy and medicaments therefor
|
ITMI20040876A1
(en)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
DEHACETYLASE-HDAC HISTONE INHIBITORS-WHICH HYPOLIPIDEMIZED AGENTS FOR THE THERAPY AND PREVENTION OF ARTERIOSCLEROSIS AND CARDIOVASCULAR DISEASES
|
ATE399539T1
(en)
|
2004-04-30 |
2008-07-15 |
Topotarget Germany Ag |
TWO-PHASE RELEASE FORMULATION CONTAINING HISTONE DEACETYLASE INHIBITOR
|
WO2005115149A2
(en)
|
2004-05-20 |
2005-12-08 |
Dow Agrosciences Llc |
Insectidal activity of a cyclic peptide
|
WO2005117930A2
(en)
|
2004-06-04 |
2005-12-15 |
Sloan-Kettering Institute For Cancer Research |
Use of thioredoxin measurements for diagnostics and treatments
|
US7470722B2
(en)
|
2004-06-10 |
2008-12-30 |
Kalypsys, Inc. |
Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
WO2006027346A2
(en)
|
2004-09-06 |
2006-03-16 |
Altana Pharma Ag |
Novel pyrazolopyrimidines
|
AU2005307814A1
(en)
|
2004-11-17 |
2006-05-26 |
The University Of Chicago |
Histone deacetylase inhibitors and methods of use
|
WO2006060382A2
(en)
|
2004-11-30 |
2006-06-08 |
Trustees Of The University Of Pennsylvania |
Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
|
WO2006060429A2
(en)
|
2004-12-03 |
2006-06-08 |
Novartis Ag |
Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
|
US20060128660A1
(en)
|
2004-12-10 |
2006-06-15 |
Wisconsin Alumni Research Foundation |
FK228 analogs and methods of making and using the same
|
GB0511266D0
(en)
|
2005-06-02 |
2005-07-13 |
Trust |
Chemical compounds
|
EP1743654A1
(en)
|
2005-07-15 |
2007-01-17 |
TopoTarget Germany AG |
Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
|
US7943568B2
(en)
|
2005-09-30 |
2011-05-17 |
The Ohio State University Research Foundation |
Antitumor agents
|
WO2007049736A1
(en)
*
|
2005-10-28 |
2007-05-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Concentration crystallizer and method
|
WO2007058896A2
(en)
|
2005-11-10 |
2007-05-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
|
WO2007061939A2
(en)
|
2005-11-18 |
2007-05-31 |
Gloucester Pharmaceuticals, Inc. |
Metabolite derivatives of the hdac inhibitor fk228
|
WO2007145704A2
(en)
|
2006-04-24 |
2007-12-21 |
Gloucester Pharmaceuticals |
Gemcitabine combination therapy
|
US8957027B2
(en)
|
2006-06-08 |
2015-02-17 |
Celgene Corporation |
Deacetylase inhibitor therapy
|
EP2040731A4
(en)
|
2006-06-09 |
2010-05-19 |
Merrion Res Iii Ltd |
Solid oral dosage form containing an enhancer
|
US7857804B2
(en)
|
2006-09-01 |
2010-12-28 |
Mccaffrey Timothy A |
Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
|
EP2450049A1
(en)
|
2006-12-29 |
2012-05-09 |
Gloucester Pharmaceuticals, Inc. |
Romidepsin-based treatments for cancer
|
EP2102230A2
(en)
|
2006-12-29 |
2009-09-23 |
Gloucester Pharmaceuticals, Inc. |
Purifiction of romidepsin
|
CN102276689A
(en)
|
2011-05-09 |
2011-12-14 |
中国药科大学 |
Chemical synthesis method of histone deacetylase inhibitor FK228 and application thereof
|